瑞典前列腺癌男性中癌症进展作为死因的证据评估
研究基于瑞典前列腺癌数据库5543例以前列腺癌为死因的男性,对495例分层样本进行病历审查,用评分系统量化疾病进展证据。结果显示,死亡年龄>85岁者无或中等进展证据的比例高于<85岁者(29% vs 14%)。5543例中估计13%(95%CI 5-19%)无或仅有中等进展证据。
要点
- 死亡年龄>85岁者无或中等进展证据比例高于<85岁者(29% vs 14%)。
- <85岁者中,低危21%、中危14%、高危8%、转移性0%无或中等进展证据。
- >85岁者各风险组无或中等进展证据比例相近:低危31%、中危29%、高危29%、转移性21%。
核心结论
- 前列腺癌进展作为死因的证据不足在老年男性和低危前列腺癌患者中更常见。
- 这对死亡统计解读有影响,尤其评估筛查和早期治疗时,老年男性(特别是诊断时局限性疾病者)被错误判定为前列腺癌死亡可能掩盖早期诊断的获益。
研究设计与样本
- 基于瑞典前列腺癌数据库(Prostate Cancer data Base Sweden)的研究框架,纳入5543例经死因登记册登记为前列腺癌死亡的男性。
- 对495/5543例分层样本进行病历审查,提取前列腺特异性抗原水平、影像学转移证据及前列腺癌治疗数据。
- 使用评分系统量化疾病进展证据。
主要发现
- 死亡年龄>85岁者无或中等进展证据比例高于<85岁者(29% vs 14%)。
- <85岁者中,无或中等进展证据比例:低危21%、中危14%、高危8%、转移性0%。
- >85岁者中,无或中等进展证据比例:低危31%、中危29%、高危29%、转移性21%。
- 5543例前列腺癌死亡男性中,估计13%(95%CI 5-19%)无或仅有中等进展证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the strength of the evidence indicative of prostate cancer (PCa) progression as the adjudicated cause of death, according to age at death and PCa risk category. PATIENTS AND METHODS: Using data from the Prostate Cancer data Base Sweden, we identified a study frame of 5543 men with PCa registered as the cause of death according to the Cause of Death Register. We assessed the evidence of PCa progression through a review of healthcare records for a stratified sample of 495/5543. We extracted data on prostate-specific antigen levels, presence of metastases on imaging, and PCa treatments, and quantified the evidence of disease progression using a points system. RESULTS: Both no evidence and moderate evidence for PCa progression was more common in men aged >85 years at death than those aged <85 years (29% vs 14%). Among the latter, the proportion with no evidence or moderate evidence for PCa progression was 21% for low-risk, 14% for intermediate-risk, 8% for high-risk, and 0% for metastatic PCa. In contrast, in men aged >85 years, there was little difference in the proportion with no evidence or moderate evidence of PCa progression between PCa risk categories; 31% for low-risk, 29% for intermediate-risk, 29% for high-risk, and 21% for metastatic PCa. Of the 5543 men who died from PCa, 13% (95% confidence interval 5-19%) were estimated to have either no evidence or moderate evidence of PCa progression. CONCLUSIONS: Weak evidence for PCa progression as cause of death was more common in older men with PCa and in those with low-risk PCa. This has implications for interpretation of mortality statistics especially when assessing screening and early treatment of PCa because the beneficial effect of earlier diagnosis could be masked by erroneous adjudication of PCa as cause of death in older men, particular those with localised disease at diagnosis.
引用
- Orrason AW, Styrke J, Garmo H, et al. Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden. BJU Int. 2022. PMID: 36088648. doi:10.1111/bju.15891
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。